autologous bone marrow transplant. From February to March 2024, he received 12 sessions of radiation therapy. Finally, from June 2024 to January 2025, Mahmoud underwent immunotherapy sessions aimed to fight any residual cancer cells. The multidisciplinary team included a pediatric oncologist, pathologists, pediatric surgeons, radiation oncologists, nuclear medicine experts, intensive care specialists, oncology pharmacists, and a social worker, among others. Each played a critical role in Mahmoud’s journey to recovery.
marrow transplant, and immunotherapy. Led by Dr. Zainul Aabideen, Consultant Pediatric Oncologist and Head of Pediatric Hematology, Oncology, and BMT, Mahmoud’s treatment began in August 2023 with a molecular genetic test at OncoHelix Co-Lab to optimize his treatments. He then underwent four rounds of chemotherapy to shrink the tumor, followed by a complex surgery to remove it. The surgery was successfully performed despite significant challenges. His last chemotherapy session was completed in November 2023. In December 2023, he underwent an
Every week, we went to the hospital. Despite his young age, Mahmoud understood the importance of his treatments and bravely endured each procedure. He was even mindful of the medical device implanted in his body, knowing it was critical for his recovery
Mahmoud’s treatment journey included chemotherapy, surgery, autologous bone marrow transplants, radiation therapy, and immunotherapy. It was the combined effort of specialists across various fields that made this remarkable recovery possible Dr. Zainul Aabideen Consultant Pediatric Oncologist and Head of Pediatric Hematology, Oncology, and BMT
Bilal Shurab, Mahmoud’s father
Feat Focus Burjeel Holdings 22
Clinical Achievements
Made with FlippingBook - professional solution for displaying marketing and sales documents online